Indobufen pharmaceutical composition and quality control method thereof

A technology of indobufen and its composition, which is applied in the field of medical technology, and can solve problems such as low dissolution rate and slow drug speed

A technology of indobufen and its composition, which is applied in the field of medical technology, and can solve problems such as low dissolution rate and slow drug speed

CN107281149AActive Publication Date: 2017-10-24HANGZHOU ZHONGMEI HUADONG PHARMA
8 Cites 3 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Indobufen pharmaceutical composition and quality control method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0119] Embodiment 1: Preparation of indobufen tablets

[0120] prescription:

[0121] Indobufen 200mg,

[0122] Lactose 40mg,

[0123] Microcrystalline Cellulose 25mg,

[0124] Croscarmellose sodium (disintegrant) 10mg,

[0125] Polyvinylpyrrolidone (binder) 5 mg,

[0126] Micropowder silica gel (flow aid) 2mg,

[0127] Magnesium stearate (lubricant) 2mg.

[0128] Preparation method:

[0129] (1) After mixing indobufen and sugar diluent, carry out pretreatment together (spray into water accounting for 10w / w% of the weight of the powder material and seal it for 18 hours); the rest of the solid materials are respectively pulverized into 80-mesh powder;

[0130] (2) Mix the pretreatment mixture obtained in step (1) with a cellulose diluent and a disintegrant accounting for 40% of the total amount;

[0131] (3) Add a binder solution (mixed with water to a concentration of 4w / v%) in advance with a solvent in the mixed material obtained in step (2), and prepare wet granules...

Embodiment 2

[0133] Embodiment 2: preparation of indobufen tablets

[0134] prescription:

[0135] Indobufen 200mg,

[0136] Lactose 30mg,

[0137] Microcrystalline Cellulose 40mg,

[0138] Crospovidone (disintegrant) 5mg,

[0139] Polyvinylpyrrolidone (binder) 8 mg,

[0140] Micropowder silica gel (flow aid) 1mg,

[0141] Magnesium stearate (lubricant) 5mg.

[0142] Preparation method:

[0143] (1) After mixing indobufen and carbohydrate diluent, carry out pretreatment together (spray into water accounting for 9w / w% of powder material weight and seal and let stand for 16 hours); the remaining solid materials are respectively crushed into 80-mesh powder;

[0144] (2) Mix the pretreatment mixture obtained in step (1) with the cellulose diluent and the disintegrant accounting for 60% of the total amount;

[0145] (3) Add a binder solution (prepared to 5w / v% concentration with 40% ethanol solution) in the mixed material obtained in step (2) with a solvent in advance, and prepare we...

Embodiment 3

[0147] Embodiment 3: Preparation of indobufen tablets

[0148] prescription:

[0149] Indobufen 200mg,

[0150] Lactose (anhydrous lactose) 50mg,

[0151] Microcrystalline Cellulose 15mg,

[0152] Sodium starch glycolate (disintegrant) 15mg,

[0153] Hypromellose (binder) 3mg,

[0154] Talc powder (glidant) 5mg,

[0155] Stearic acid (lubricant) 1mg.

[0156] Preparation method:

[0157] (1) After mixing indobufen and carbohydrate diluent, carry out pretreatment together (spray into water accounting for 8w / w% of the weight of the powder material and seal it for 20 hours); the remaining solid materials are respectively pulverized into 80-mesh powder;

[0158] (2) Mix the pretreatment mixture obtained in step (1) with the cellulose diluent and the disintegrant accounting for 50% of the total amount;

[0159] (3) Add the binder solution (mixed to 3w / v% concentration with 70% ethanol solution) in the mixed material obtained in step (2) with a solvent in advance, and pre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an indobufen pharmaceutical composition and a quality control method thereof. Particularly, the indobufen pharmaceutical composition contains the following components in parts by weight: 200 parts of indobufen, 30-50 parts of saccharide diluents, 15-40 parts of a fiber diluents, 5-15 parts of a disintegrating agent, 3-8 parts of an adhesive, 1-5 parts of a flow aid and 1-5 parts of a lubricant, wherein the saccharide diluents are selected from mannitol, saccharose, lactose, fructose, glucose, sorbitol, hydrates of the saccharides, and a combination of the saccharides and hydrates. The invention further relates to a preparation method, quality control method and pharmaceutical use of the composition. The indobufen pharmaceutical composition can be used for treating arteriosclerotic ischemic cardiovascular diseases, ischemic cerebrovascular disease and peripheral arterial disease, blood lipid dysbolism, venous thrombosis and diabetes mellitus and preventing thrombosis during extracorporeal circulation operation and presents excellent effects as described in description.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a medicine that can be used for the prevention of arteriosclerotic ischemic cardiovascular disease, ischemic cerebrovascular disease and peripheral arterial disease, dyslipidemia, venous thrombosis, diabetes and cardiopulmonary bypass surgery. The indobufen pharmaceutical composition of thrombosis, particularly relates to a kind of indobufen tablet pharmaceutical composition with excellent pharmaceutical properties, and the present invention also relates to the preparation of this indobufen pharmaceutical composition with excellent pharmaceutical properties Methods of preparation, and their quality control methods. Background technique [0002] Indobufen pharmaceutical composition related to the present invention, its active ingredient is indobufen, Indobufen, Chinese chemical name: (±) 2-[4-(1-oxo-2-isoindolinyl) Phenyl]butyric acid, or (±)2-[4-(1-oxo-2-isoindolinyl)phenyl]butyr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
24 Oct 2017
Publication
CN107281149A
IPC
A61K9/20; A61K31/404; A61K47/26; A61K47/38; A61P9/10; A61P7/02; A61P3/10; A61P3/06; G01N21/33
CPC
A61K9/2018; A61K9/2054; A61K9/2072; A61K9/2077; A61K9/2095; A61K31/404; G01N21/33
Inventors
韩敏; 刘玉艳